FFM
TIL icon

Fairmount Funds Management’s Instil Bio TIL Stock Holding History

Fairmount Funds Management’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-33,695
Closed -$3.26M – 26
2022
Q3 		$3.26M Hold
33,695
– – 0.57% 26
2022
Q2 		$3.11M Hold
33,695
– – 0.71% 25
2022
Q1 		$7.24M Hold
33,695
– – 1.71% 17
2021
Q4 		$11.5M Hold
33,695
– – 3.8% 10
2021
Q3 		$12M Hold
33,695
– – 4.38% 11
2021
Q2 		$13M Buy
33,695
+6,195
+23% +$2.3M 5.35% 6
2021
Q1 		$13.8M Buy
+27,500
New +$14.1M 5.81% 8

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fairmount Funds Management's TIL Position: Q4 2022 in Review

Fairmount Funds Management sold out of Instil Bio (TIL) in Q4 2022, closing a stake of 33,695 shares — an estimated $3.26M sold.

Fairmount Funds Management first reported a position in TIL in Q1 2021 and held it in 7 quarters. The position peaked at $13.8M in Q1 2021. 78 funds tracked by Wall St. Rank hold TIL as of Q4 2022.

  • Fairmount Funds Management reported no remaining Instil Bio position as of Q4 2022 after selling out during the quarter.
  • Fairmount Funds Management sold 33,695 Instil Bio shares in Q4 2022, an estimated $3.26M.
  • Fairmount Funds Management first reported a position in Instil Bio in Q1 2021 and held it in 7 quarters.
  • Fairmount Funds Management's Instil Bio position peaked at $13.8M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Instil Bio as of Q4 2022.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.